Bio-Path Holdings announced an upcoming poster presentation at the 2024 European Hematology Association, EHA, Congress, taking place June 13-16, 2024 in Madrid, Spain. Jorge Cortes, M.D., Director of the Georgia Cancer Center, will present interim results from the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. The data show prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPTH:
- Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
- Bio-Path Holdings Reports First Quarter 2024 Financial Results
- Bio-Path reports Q1 EPS ($4.88) vs ($13.25) last year
- BPTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
Questions or Comments about the article? Write to editor@tipranks.com